Letrozole after tamoxifen for breast cancer - What is the price of success?

被引：33

作者：

Bryant, J ^{[1
]}

Wolmark, N

机构：

[1] Natl Surg Adjuvant Breast & Bowel Project, Pittsburgh, PA USA

[2] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA

[3] Allegheny Gen Hosp, Dept Human Oncol, Pittsburgh, PA 15212 USA

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2003年 / 349卷 / 19期

关键词：

D O I：

10.1056/NEJMe038167

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1855 / 1857

页数：3

共 4 条

[1]

*EARL BREAST CANC, 2000, EARL BREAST CANC TRI

[2] Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer [J].

Gail, MH ;

Costantino, JP ;

Bryant, J ;

Croyle, R ;

Freedman, L ;

Helzlsouer, K ;

Vogel, V .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (21) :1829-1846

[3] A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer [J].

Goss, PE ;

Ingle, JN ;

Martino, S ;

Robert, NJ ;

Muss, HB ;

Piccart, MJ ;

Castiglione, M ;

Tu, D ;

Shepherd, LE ;

Pritchard, KI ;

Livingston, RB ;

Davidson, NE ;

Norton, L ;

Perez, EA ;

Abrams, JS ;

Therasse, P ;

Palmer, MJ ;

Pater, JL .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (19) :1793-1802

[4]

*NAT CANC I CAN CL, 2003, PHAS 3 RAND DOUBL BL

← 1 →